Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

WCLC 2026

Lung, Respiratory and Thoracic Cancer

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial

Lancet Oncol

Zhang L, Zhang X, Wu L, Xing W, Liu C, Zhang P, Chen K, Shi J, Xu S, Zhang X, Dong X, Fang H, Yu X, Gao Y, Li G, Chen Z, Fan S, Zhang X, Cheng Y

doi: 10.1016/S1470-2045(25)00643-6

Lung, Respiratory and Thoracic Cancer

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Lung Cancer

Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC, European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group

doi: 10.1016/j.lungcan.2025.108798

Lung, Respiratory and Thoracic Cancer

Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study

Lung Cancer

Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C

doi: 10.1016/j.lungcan.2025.108885

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME

doi: 10.1016/j.lungcan.2026.108936

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Dingemans AC, Opitz I, Brunelli A, Remon J, Hendriks LEL, Edwards J, Faivre-Finn C, Reguart N, Smit EF, Levy A, Sanchez-Lorente D, Trujillo JC, Filippi AR, Stathopoulos K, Blum TG, Guckenberger M, Popat S, De Angelis R, Hofman P, von der Thüsen J, Hartemink KJ, Petersen RH, Ruffini E, Dickhoff C, Houda I, Prisciandaro E, De Ruysscher D, Derks J, Bahce I, Mariolo A, Besse B, Xenophontos E, Giaj Levra N, van Schil P, Brandão M, Berghmans T

doi: 10.1016/S2213-2600(26)00051-2

Lung, Respiratory and Thoracic Cancer

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Lancet

Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W, SACHI Study Group

doi: 10.1016/S0140-6736(25)01811-2

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Related content

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study

Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial